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Overview of Thesis 
 
The aim of the study was to look for a safe alternative to a disfiguring total orbital 
exenteration for orbital squamous cell carcinoma, so that a standard hospital issue inexpensive 
stock ocular prosthesis can be fitted with improved aesthetic results, rather than an expensive 
custom made prosthesis for the patient’s own cost.  
The subjects and methods involved a retrospective case review which was performed of 
patients from St Aidan’s Missionary Hospital initially, which was later amalgamated into the 
McCords Provincial Eye Hospital, Durban, KwaZulu-Natal, South Africa. Ten consecutive patients 
who underwent an ‘extended’ lid-sparing subtotal exenteration with minimally preserved 
healthy conjunctiva and a buccal mucosal graft were identified over a 3 year period from 1 
January 2011 to 31 December 2013. Patients’ clinical records were reviewed. 
Results included all of the ten patients having a good aesthetic outcome at 4 weeks and six 
months with a standard hospital issue stock ocular prosthesis. One patient had a repeat buccal 
mucosal graft after forniceal shortening. Three patients had local recurrences within one year 
but all recurrences were identified easily and total exenteration was successfully performed. 
The survival rate at 3 years was ninety percent as one patient was lost to follow-up. 
 
A subtotal orbital exenteration with minimally preserved healthy conjunctiva and a buccal 
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PART 1: INTRODUCTION 
 
The purpose of this retrospective study was to look for a safe alternative to a disfiguring 
total orbital exenteration for orbital squamous cell carcinoma, so that a standard hospital issue 
inexpensive stock ocular prosthesis can be fitted with improved aesthetic results, rather than 
an expensive custom made prosthesis for the patient’s own cost. Records were reviewed from 
1 January 2011 to 31 December 2013 from the McCords Provincial Eye Hospital, KwaZulu-Natal, 
South Africa. 
 
SQUAMOUS CELL CARCINOMA OF THE EYE:  
“Understanding the disease and therapeutic options” 
Ocular squamous cell carcinoma of the cornea and conjunctiva was first described in the 
19th century [1].  Ocular surface squamous neoplasia (OSSN) was later used to describe 
intraepithelial and invasive squamous cell carcinoma of the cornea and conjunctiva [2].  This is 
further broken down into:  
A) Conjunctival intraepithelial neoplasia (CIN/ conjunctival dysplasia). CIN involves 
replacement of the normal conjunctival epithelium by atypical squamous cells. Mild dysplasia 
involves less than fifty percent thickness of the epithelial layer, whereas severe dysplasia 
involves more than fifty percent.  
B) Carcinoma in situ (CIS) is the replacement of full thickness epithelium by dysplastic cells, 
however the basement membrane remains intact.  
C) Invasive squamous cell carcinoma (SCC) represents malignant cells which have broken 
through the epithelial basement membrane. 
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Presenting symptoms may be asymptomatic, or a conjunctival lump, ocular surface redness, 
irritation, pain, blurred vision, etc. Clinical appearance includes any of the following: no specific 
lesion seen, leukoplakia (white keratinization), fibrotic, gelatinous, fleshy, papillomatous, 
papillary, vascular, nodular, diffuse or pigmented[3]. Size and distribution is varied. 
Risk factors for OSSN include: male gender, advanced age, ultraviolet light exposure, 
xeroderma pigmentosum, blonde hair, light complexion, cigarette smoking, human 
papillomavirus, and atopic disease [4,5,6]. There is a higher occurrence in patients with HIV[7].  
Investigations range from histopathological confirmation of the disease either with an 
incisional or excisional biopsy. Impression cytology when available has a positive predictive 
accuracy of 97.4% when compared to tissue histology [8].  
Radiological imaging with Computerized Tomography (CT) scan for extent of surgical planes, 
bone involvement and brain metastasis. Ideally, a MRI is best suited for clearer tissue 
involvement, however access to this is limited. General abdominal ultrasound imaging and 
chest x-rays for metastatic assessment is included. Haematological workup is part of this 
workup too. A general physical examination must include lymph node assessments with 
palpation and ideally fine needle biopsies performed on suspiciously enlarged lymph nodes. 
Treatment is aimed at complete eradication of the tumour mass with the primary goal of 
saving the patient’s life and saving the vision as the secondary goal[9]. Treatment modalities 
range from medical non-invasive methods, simple excision to exenteration.  Management plans 
are individualized, however this is guided by the size of the lesion (basal area and thickness), 
lesion location, invasiveness of the lesion, the fellow eye status and the general health and age 
of the patient[10].  
Discrete non-invasive masses of the cornea or conjunctiva can be treated with mitomycin C 
or 5-fluorouracil topical chemotherapeutic agents[11-13], topical and or intralesional 
immunotherapy with Interferon alpha-2b[14] or simple excision[15]. With a simple excision, 
frozen section technique[16] is preferred to obtain clear surgical margins or modified Moh’s 
micrographic technique[17]. However many of the above modalities are not widely available. 
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  Further to this would be other globe preserving treatment options for invasive OSSN, 
which can include varied combinations of topical chemoreduction, topical and or intralesional 
Interferon alpha, surgical excision, cryotherapy or brachytherapy[18-22]. When a lesion invades 
the anterior orbit or if there is a recurrence of the tumour which is not amenable to medical 
treatment or combination therapy, then an exenteration is the treatment of choice[23].  
Understanding what options are available for an orbital exenteration and which patients are 
suitable for such options are very important. An orbital exenteration can be either a total, 
subtotal or extensive exenteration. A total exenteration involves the removal of the eyelids, 
conjunctiva, globe, entire orbital contents including the periorbita [24]. A subtotal exenteration 
may spare the eyelids and periorbita, but removes the globe, and extraocular muscles [25]. An 
extended or superexenteration is the most aggressive, involving everything as with a total 
exenteration, as well as removal of the bony orbital walls, surrounding paranasal sinus tissues 
and/or intracranial tissue.  
The following classification by Goldberg et al[9] was utilized for this study: ”Orbital 
exenteration was either total or subtotal based on the following criteria: Total exenteration 
procedures involved removal of the entire orbital contents including the periorbita, whereas 
subtotal exenterations preserved at least a quadrant of the orbit or the apical orbital tissues 
posterior to the globe. Exenteration procedures were then subclassified as eyelid-sparing, 
conjunctival-sparing and globe-sparing procedures. Eyelid-sparing and conjunctival-sparing 
procedures were defined as those in which 50% or more of the patient’s pretarsal eyelid or 
bulbar conjunctiva was preserved.” 
The above methods are tailored to individual patients based on their disease process (eyelid 
or orbital malignancy or infection); the extent of tissue involvement; the health status of the 
patient as well as the patient’s desires. Treatment is either lifesaving, for disease control, 
palliative or cosmetic.  
A subtotal exenteration is recommended where tumour free margins can be obtained and is 
more successful if this is achieved before distant metastasis occurs[26]. A total exenteration is 
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aimed at extensive anterior or posterior orbital involvement with or without bony involvement. 
It can take months to fully heal, frequent wound dressing changes and follow-ups are required 
and complications are often encountered. Complications include: fistula or sinus formation, 
infection, orbital abscesses, tissue necrosis or eschar formation, non-healing ulcer or implant 
exposure. A subtotal exenteration as in this study was aimed at less extensive anterior orbital 
involvement since preservation of some orbital tissues facilitates completion of the primary 
reconstruction. Healing is much faster and complications are infrequent.  
 Rehabilitation of an exenterated socket can be either by primary granulation and secondary 
skin flaps or muscle to cover the defect. Prosthetic implants can be titanium osseointergrated 
implants attached with magnetic clips or prosthesis attached to the frame of spectacles. 
Goldberg et al, found that in their series of patients, many patients resort to just wearing an 
eye patch.  
 
BACKGROUND TO THE STUDY 
In KwaZulu-Natal, and more specifically at the study hospital, patients are of very poor 
socio-economic standing. Many patients cannot afford basic transportation for medical 
assistance. Whilst priority is given to the curative process, cosmetic rehabilitation can be very 
difficult and expensive for the patient as institutional budgets do not cover the expenses of 
custom made prostheses for every patient.   
Patients that have had a subtotal exenteration heal faster with fewer complications and 
thus require fewer postoperative wound management follow-ups which can also be quite 
expensive for the individual patient.  
The patients identified in this study were less than 50 years old and all were HIV positive. 
Previously reported studies have shown a relationship between patients less than 50 years old 
with conjunctival squamous cell carcinoma and the presence of HIV[27]. A higher grade of 
malignancy is more common in HIV positive patients as opposed to HIV negative patients[28]. 
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Patients whose HIV status was unknown at diagnosis were also tested for HIV as it has been 
suggested that underlying HIV may have OSSN as one of the first manifestations[29]. 
Immunocompromised patients heal slower than their Immunocompetent counterparts, and 
thus also brings forth the need for a therapeutic option with a shorter recovery period. 
 
SUBJECTS AND METHODS 
A retrospective case review was performed of patients from St Aidan’s Missionary Hospital 
initially, which was later amalgamated into the McCords Provincial Eye Hospital, Durban South 
Africa. Ten consecutive patients who underwent a lid-sparing subtotal exenteration with buccal 
mucosal graft were identified over a 3 year period from 1 January 2011 to 31 December 2013. 
Patients’ clinical records were reviewed. 
The following information was obtained from each patients’ records: Age, gender, 
involvement of which eye (laterality); whether or not the diagnosis was made on incisional 
biopsy, duration of symptoms before presentation, radiological extent of the tumour, Human 
Immunodeficiency Virus (HIV)  status, type of primary surgery, histopathological clearance of 
surgical margins, aesthetic follow-ups at 1 week, 1 month, 2 months and 6 months and 
standard cancer follow ups at 1 year to 3 years; outcome and any surgical revisions. 
The inclusion criteria included all patients that had subtotal orbital exenteration with buccal 
mucosal graft for histologically confirmed squamous cell carcinoma. Exclusion criteria were that 
of tumours that involved the bony orbit, the posterior 1/3 of orbital contents or that had 
metastatic spread at the time of diagnosis. 
No patients with medial canthal or caruncle involvement were considered for this 
procedure, as these have been found to have a high rate of recurrence [30, 31].  
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  The minimally preserved healthy conjunctiva in this study was twenty percent, which is 
markedly reduced from the technique described by Goldberg et al, in 2003, in which a 
minimum of fifty percent of healthy conjunctiva was preserved.  
All surgeries were performed by the same surgeon. The first step of the procedure under 
general anaesthesia involved the Shields “No-Touch Technique” [15] enucleation and tumour 
excision with 4mm clearance margins from macroscopically affected conjunctiva (Fig 1 & 2). 
This achieved preservation of approximately twenty percent of the lateral bulbar conjunctiva, 
and approximately forty percent of orbital fat and soft tissue laterally. The surgical plane for a 
temporal mass extended to the bony orbital wall with removal of periosteum, muscles, orbital 
fat and other orbital soft tissue (Fig 3). A 3 cm × 2 cm buccal mucosal graft was harvested from 
the left cheek of the patient [32]. The prepared mucosa was sutured directly to the remaining 
lateral bulbar conjunctiva and forniceal conjunctiva nasally with 8/0 silk interrupted sutures (Fig 
4 & 5). Forniceal deepening sutures were placed, chloramphenicol ointment instilled, and a 
conformer was positioned which was removed after 4 weeks and a standard issue hospital 
prosthetic shell was fitted (Fig 6). Using identical surgical principles all ten patients had very 
similar surgeries. (Data results Appendix 4) 
 
SUMMARY 
This method highlights that for even larger masses, the patient does not have to undergo a 
total exenteration, but rather have this form of ‘extended’ subtotal exenteration with an 
acceptable cosmetic outcome. Whilst cure of the disease process is pivotal, rehabilitation and 
cosmesis of the survivor has to be considered in the primary management plan.  
The use of a buccal mucosal graft for a subtotal exenteration can be performed at the 
primary surgery with faster rehabilitation using an inexpensive artificial eye. This is especially 
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Aim:  To look for a safe alternative to a disfiguring total orbital exenteration, so that an 
inexpensive stock ocular prosthesis can be fitted with improved aesthetic results, rather than 
expensive onlay prosthesis. 
Methods: Retrospective case series of ten consecutive patients that had a subtotal lid-
sparing exenteration with preservation of minimal conjunctiva, and buccal mucosal graft for 
orbital squamous cell carcinoma. Records were reviewed from 1 January 2011 to 31 December 
2013 from the McCords Provincial Eye Hospital, South Africa. 
Results: Of the ten patients all had good aesthetic results at 4 weeks as well as at six 
months. One patient had a repeat buccal mucosal graft after forniceal shortening. Three 
patients had recurrences within one year and total exenterations were successfully performed. 
The survival rate at 3 years was ninety percent. 
Conclusions: A subtotal orbital exenteration, preserving minimal conjunctiva, with a buccal 




SYNOPSIS: A subtotal exenteration, for anterior orbital squamous cell carcinoma, with 
minimally preserved conjunctiva and a buccal mucosal graft, can be cost effective, safe and 
cosmetically acceptable with a standard ocular prosthesis. 
 





An orbital exenteration can be classified as Total, Subtotal (or Lid Sparing) or Extensive 
(which may involve removal of paranasal sinuses) [1]. An exenteration is indicated for either 
curative, including inflammation or infection considered to be life threatening or palliative 
therapy, and as in the case of advanced or metastatic disease, for debulking with or without 
radiotherapy.  
No matter what type of exenteration is performed, it is physically and psychologically 
disfiguring for every patient to some degree. 
 
Goldberg et al, in 2003, described a subtotal exenteration with preservation of at least a 
quadrant of the orbit or apical tissues[2]. With their technique, a minimum of 50% of 
conjunctiva needed preservation to maintain an ocular prosthesis. In this study a minimum of 
20% of residual conjunctiva was found to be equally efficacious in maintaining an ocular 
prosthesis with the use of a buccal mucosal graft. The mucosal graft forms a stable base, and 
can be removed, re-sited or re-grafted if needed for recurrences, dehiscence or infection. 
 
In KwaZulu-Natal, South Africa, many patients are of very poor socio-economic standing. 
Whilst priority is given to the curative process, cosmetic rehabilitation can be very difficult and 
expensive for the patient as institutional budgets do not cover the expenses of custom made 
prostheses for every patient.   
Patients that have had a subtotal exenteration heal faster with fewer complications and 
thus require fewer postoperative wound management follow-ups which can also be quite 
expensive for the individual patient. 
 
The purpose of this study was to identify a safe alternative to a disfiguring total 
exenteration so that improved cosmesis can be achieved with an inexpensive stock ocular 
prosthesis. 
 
MATERIALS AND METHODS 
A retrospective case review was performed of patients from St Aidan’s Missionary Hospital 
initially, which was later amalgamated into the McCords Provincial Eye Hospital, Durban South 
Africa. Ten consecutive patients who underwent a lid-sparing subtotal exenteration with buccal 
mucosal graft were identified over a 3 year period from 1 January 2011 to 31 December 2013. 
Patients’ clinical records were reviewed. 
 
The following information was obtained from each patients’ records: Age, gender, 
involvement of which eye (laterality); whether or not the diagnosis was made on incisional 
biopsy, duration of symptoms before presentation, radiological extent of the tumour, Human 
Immunodeficiency Virus (HIV)  status, type of primary surgery, histopathological clearance of 
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surgical margins, aesthetic follow-ups at 1 week, 1 month, 2 months and 6 months and 
standard cancer follow ups at 1 year to 3 years; outcome and any surgical revisions. 
The inclusion criteria included all patients that had subtotal orbital exenteration with buccal 
mucosal graft for histologically confirmed squamous cell carcinoma. Exclusion criteria were that 
of tumours that involved the bony orbit, the posterior 1/3 of orbital contents or that had 
metastatic spread at the time of diagnosis. 
 
No patients with medial canthal or caruncle involvement were considered for this 
procedure, as these have been found to have a high rate of recurrence [3;4].  
 
The preoperative assessment included patient counselling, inscisional biopsy and 
histological confirmation of squamous cell carcinoma, radiological imaging to delineate the 
extent of localised tumour margins, bony involvement and the presence of metastases. A 
general systemic review and examination including lymph node assessments were performed 
for possible metastasis. Haematological investigations, chest x-ray, abdominal ultrasound or CT 
imaging also formed part of the metastatic workup. A tailored management plan involved 
patient counselling, available surgical options, including a lid sparing subtotal exenteration or a 
subtotal exenteration with a buccal mucosal graft, and post-operative management and 
rehabilitation for the above. A total exenteration was also part of the counselling process as 
either primary surgery or as secondary surgery, if surgical margins were not clear from the 
tumour, or other complications like severe infection, etc. 
 
Surgical technique:   All surgeries were performed by the same surgeon. Clinical and radiological 
surgical planes were identified, as in the case of patient ”A” a nasal mass, 10 mm diameter, 
eight limbal clock hour mass involving conjunctiva, sclera and cornea while sparing the 
caruncle, palpebral conjunctiva and fornices (Fig 1). The first step of the procedure under 
general anaesthesia involved a “No-Touch Technique” [5] enucleation and tumour excision with 
4mm clearance margins from macroscopically affected conjunctiva (Fig 2). This achieved 
preservation of approximately twenty percent of the lateral bulbar conjunctiva, and 
approximately forty percent of orbital fat and soft tissue laterally. The surgical plane for a 
temporal mass extended to the bony orbital wall with removal of periosteum, muscles, orbital 
fat and other orbital soft tissue (Fig 3). 
 
After removal of the main tumour block, marked additional specimens were taken for 
histology to confirm completeness of the tumour excision. Haemostasis was achieved. 
A 3 cm × 2 cm buccal mucosal graft was harvested from the left cheek of the patient [6]. The 
prepared mucosa was sutured directly to the remaining lateral bulbar conjunctiva and forniceal 
conjunctiva nasally with 8.0 silk interrupted sutures (Fig 4). 
Forniceal deepening sutures were placed, chloramphenicol ointment instilled, and a 
conformer was positioned which was removed after 4 weeks. All patients were sent home with 
paracetamol oral analgesia, chloramphenicol ointment and an antiseptic mouthwash. 
 





Ten eyes of ten patients were identified for inclusion in the study. Patient ages ranged from 
34 to 49 years old, with a mean age of 41.5 years. There were 6 female and 4 male patients. Of 
the ten eyes, three were left eyes and seven were right eyes. The duration of symptoms for 
each patient varied between three months to seven months with a mean of five months. All 
tumours were confirmed histopathologically as invasive squamous cell carcinoma on initial 
incisional biopsy.  
 
Patient “A” initially refused primary surgical treatment after counselling. A trial of 6 cycles 
of Mitomycin C was offered for the duration of further patient counselling. The patient 
subsequently agreed to a subtotal exenteration. Patient “C“ defaulted primary surgery, but 
returned 6 months later, was re-evaluated and underwent a subtotal exenteration. Patient “G“ 
refused all forms of treatment, but returned 6 months later and had a subtotal 
exenteration(Table 1) . Of the 3 patients that refused initial surgery, Patient “G” had a 
recurrence of the primary tumour at 9 months after primary surgery and went on to have a 
total exenteration. 
 
All patients had Computerized Tomography (CT) scan radiological imaging as part of the 
preoperative assessment for surgical planes and as part of their metastatic workup. Six patients 
had anterior scleral involvement. Four patients had anterior sclera with either anterior medial 
rectus muscle or lateral rectus muscle involved. No patients had clinical metastasis noted by 
either systemic examination, including lymph node assessment by palpation, haematological 
tests and chest x-ray, CT or abdominal ultrasound imaging.  
 
 All ten patients were HIV positive, either previously known or diagnosed at presentation. 
The primary surgery after definitive diagnosis for all patients was a lid-sparing subtotal 
exenteration with a buccal mucosal graft. All surgical margins were reported clear of tumour on 
histological examination.  
 
At four weeks follow-up all ten patients had healthy and viable mucosal graft tissue in their 
orbits (Fig 5). The harvest site of the buccal graft had healed well in all patients. All ten patients 
had a successful stock prosthetic eye fitting at this time (Fig 6). The choice of prosthesis was 
restricted to the institutional budget and the patients’ financial constraints. The sizes, shapes 
and colour variants of the prosthetic shells were standard issue as this was limited by the 
institutional budget. 
 
Patient “E” had a repeat buccal mucosal graft and forniceal deepening five months after the 
primary surgery due to forniceal shortening and inability to readily retain a prosthesis. At six 





Patients “I”, “G” and “F” had recurrence of the primary carcinoma on routine follow up at 
six months, nine months and one year respectively, and all went on to have a total orbital 
exenteration. These patients used a standard eye patch for final cosmesis. All three patients are 
tumour-free at the 3 year cancer follow-up. Patient “J” defaulted the routine one year follow-
up and all contact attempts were in vain (Table 2). All other patients were cancer free at their 3 
year routine cancer follow up. The survival rate at 3 years was ninety percent, as patient “J” was 
lost to follow up and presumed deceased. 
DISCUSSION 
 
Patients presented relatively late, as they had already surpassed the more conservative 
treatment options, such as is the case in non-invasive Ocular Surface Squamous Neoplasia 
(OSSN) with mitomycin C or 5-fluorouracil topical chemotherapeutic agents[7-9], or simple 
excision. Further to this would be other globe preserving treatment options for invasive OSSN, 
which can include varied combinations of topical chemoreduction, topical and or intralesional 
Interferon alpha, surgical excision, cryotherapy or brachytherapy[10-14]. Treatment options at the 
study hospital were limited to mitomycin C, 5-fluorouracil and surgical management. 
 
 
 Ideally, an MRI would have also been preferred for better imaging and delineation of 
preoperative tissue planes, however this was not readily available. Other useful imaging 
options, that were also not available to these patients for anterior segment involvement, 
especially angle involvement if not clear on gonioscopy, is the use of ultrasound biomicroscopy 
and ultra-high resolution optical coherence tomography (UHR-OCT), which is also beneficial to 
identify any anterior scleral/ciliary body masses[15,16]. 
 
The patients identified in this study were less than 50 years old and all were HIV positive. 
Previously reported studies have shown a relationship between patients less than 50 years old 
with conjunctival squamous cell carcinoma and the presence of HIV[17]. A higher grade of 
malignancy is more common in HIV positive patients as opposed to HIV negative patients[18,19]. 
Patients whose HIV status was unknown at diagnosis were also tested for HIV as it has been 
suggested that underlying HIV may have OSSN as one of the first manifestations[20].  
 
A total exenteration is aimed at extensive anterior or posterior orbital involvement with or 
without bony involvement. It can take months to fully heal, frequent wound dressing changes 
and follow-ups are required and complications are often encountered. Deep exposed sockets 
are psychologically disturbing to the patient[21]. A subtotal exenteration as in this study is aimed 
at less extensive anterior orbital involvement since preservation of some orbital tissues 
facilitates completion of the primary reconstruction. Healing is much faster and complications 




With both techniques a biopsy can be easily accessed if recurrences are suspected. In the 
case of a subtotal exenteration with a buccal mucosal graft, the graft can easily be detached or 
removed, a biopsy taken, and the graft re-sited. In the event of possible complications such as 
wound sepsis, graft dehiscence, late socket bleed, etc., the mucosal graft can be removed, the 
wound managed and once stable, the patient can undergo a repeat buccal mucosal graft. The 
use of the prosthetic shell lends for ease of removal, disinfection and reinsertion by the patient, 
as well as self-monitoring of the graft integrity. Patients need to be counselled about 
preventing micro trauma to the graft after the initial 4 week convalescent phase, as this may be 
a nidus for infection and graft dehiscence. 
 
For better orbital volume, a dermis fat graft can be incorporated into the primary 
surgery[22]. Placing a ball implant for orbital volume may also be an option, however extrusion 
would be a risk factor as the non-vascularized buccal mucosal graft may be inadequate to 
maintain the implant in situ. 
 
Whilst all patients had clear surgical margins on histolological examination, which included 
no tumour cells found at the free margins of all biopsied specimens, 3 patients (30 %) had a 
recurrence of the primary tumour. There is controversy surrounding subtotal exenterations and 
local control or metastasis[23], as surgical marginal clearance is not always indicative of a cure 
since micro-metastasis may be a culprit[24]. Also to consider is a higher recurrence occurs in HIV 
individuals, as described by Makupa et al. The relationship between a patient’s CD4 count (a 
low CD4 count) and recurrence rate may provide future predictive outcomes, however a larger 
prospective study might be of value. 
 
Patients with carcinoma of the eye and or adnexa need an exclusive management plan 
which involves patient counselling, histological confirmation, radiological imaging to delineate 
the extent of localised tumour margins, bony involvement and the presence of metastases. Of 
critical importance is that patients be involved in this plan as post-surgical follow-ups are life-
long. Financial constraints of the patient and institutional resources are also of paramount 
importance. 
 
A limitation of this study is that this procedure is limited to non-extensive anterior 
involvement of tumour, in which surgical clearance of the primary tumour is anticipated with 
the primary surgery.  Due to the rarity, variance of invasiveness of tissue planes and debilitating 
nature of the disease it is difficult to do prospective randomisation or get numbers large 
enough to be statistically significant. 
 
In conclusion, all patients had histological surgical clearance with the minimally preserved 
conjunctiva and with cosmetic rehabilitation within four weeks. The study achieved the primary 
goals of being cost effective and cosmetically acceptable for the study subjects. There was a 
thirty percent recurrence rate but recurrences were easily identified and managed. 









Fig 1: A large nasal mass, not involving the 
caruncle.  
  
Fig 2: Nasal mass: Enucleation nasally, 
removing muscles, orbital tissue and periosteum. 
 
Fig 3: Temporal mass: Periosteum removed 
temporally, with clean bone. Nasal orbital tissue 
remaining. 
 
Fig 4: Buccal mucosal graft sutured to 
conjunctiva and fornix 
 
Fig 5:  Buccal mucosa nasal 3/4 and temporal ¼ 
with remnant conjunctiva   
  
Fig 6: Stock ocular prosthesis fitting at 1 month 
follow up. Inset: Standard stock ocular prosthetic shells
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Status  and CD4 
count
A 47 F R 6 months.
Trial of Mitomycin C 6 
cycles
Yes Anterior  cornea & sclera HIV +
175
B 34 F L 4 months Yes Anterior sclera HIV +
430
C 40 F L 1 year,  defaulted. 
Returned 6 months later
Yes Anterior sclera HIV +
385




E 49 F R 6 months Yes Anterior sclera HIV +
118




G 43 M L 6 months Refused 
treatment. Returned 6 
months later








I 36 M R 6 months Yes Anterior sclera HIV +
435























A Buccal mucosa healthy Stock eye inserted Stock eye placement 
stable
Patient satisfied None
B Buccal mucosa healthy Stock eye inserted Stock eye placement stable Patient satisfied None
C Buccal mucosa healthy Stock eye inserted Stock eye placement 
stable
Patient satisfied None
D Buccal mucosa healthy Stock eye inserted Stock eye placement stable Patient satisfied None
E Buccal mucosa healthy Stock eye inserted Stock eye placement 
stable
Patient satisfied Forniceal deepening and 
repeat buccal mucosa at 5 
months
F Buccal mucosa healthy Stock eye inserted Stock eye placement stable Patient satisfied Recurrence at 1year. Total 
exenteration
G Buccal mucosa healthy Stock eye inserted Stock eye placement 
stable
Patient satisfied Recurrence at 9 months. Total 
exenteration
H Buccal mucosa healthy Stock eye inserted Stock eye placement 
stable
Patient satisfied None
I Buccal mucosa healthy Stock eye inserted Stock eye placement stable Patient satisfied Recurrence at 1 year. Total 
exenteration
J Buccal mucosa healthy Stock eye inserted Stock eye placement stable Patient satisfied Defaulted 1 year follow up
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Appendix 5: Images 
 
  
Fig 1: A large nasal mass, not involving the 
caruncle.  
  
Fig 2: Nasal mass: Enucleation nasally, 
removing muscles, orbital tissue and periosteum. 
 
Fig 3: Temporal mass: Periosteum removed 




Fig 4: Buccal mucosal graft sutured to 
conjunctiva and fornix 
 
Fig 5:  Buccal mucosa nasal 3/4 and temporal ¼ 
with remnant conjunctiva   
  
Fig 6: Stock ocular prosthesis fitting at 1 month 
follow up. Inset: Standard stock ocular prosthetic shell 
